Yahoo3h
Tens of thousands to be recruited into Alzheimer’s trials after landmark drug rejected
The National Institute for Health and Care Excellence (Nice) confirmed on Wednesday that it would not fund donanemab - the ...
Lilly’s Kisunla does not demonstrate “good value” for UK’s NHS
The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.
National Institute for Health and Care Excellence22h
New Alzheimer’s treatment donanemab does not currently demonstrate value for the NHS says NICE
Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...
The Pharma Letter16h
Second Alzheimer’s drug, donanemab, rejected for NHS use
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved US pharma major Eli Lilly’s Kisunla (donanemab ...
ITV12h
Alzheimer’s drug rejected for NHS use: What is Donanemab?
This comes as the Medicines and Healthcare Products Regulatory Agency (MHRA) said in August the drug, Donanemab, manufactured by pharmaceutical giant Eli Lilly, could be licensed for use in the UK.
Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’
A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal ...